INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey Skolnik, MD
Inovio Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Cancer Center
Phoenix, Arizona, United States
- H. Lee Moffitt Cancer Center & Research Institute, Inc.
Tampa, Florida, United States
- Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
- Columbia University, Herbert Irving Comprehensive Cancer Center
New York, New York, United States
- New York University Langone Medical Center - Perlmutter Cancer Center
New York, New York, United States
- University of North Carolina School of Medicine
Chapel Hill, North Carolina, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Greenville Memorial Hospital
Greenville, South Carolina, United States
- Inova Melanoma and Skin Cancer Center
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 May 2018
- Primary completion
- 9 May 2025
- Completion
- 9 May 2025
- Last update posted
- 10 Jul 2025
- Registered enrollment
- 35
- Registry id
- NCT03502785
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.